Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

684 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients.
Loupakis F, Antoniotti C, Cremolini C, Zhang W, Yang D, Wakatsuki T, Bohanes P, Schirripa M, Salvatore L, Masi G, Ricci V, Graziano F, Ruzzo A, Benhaim L, Marmorino F, Ning Y, El-Khoueiry R, Falcone A, Lenz HJ. Loupakis F, et al. Among authors: lenz hj. Pharmacogenomics J. 2014 Aug;14(4):322-7. doi: 10.1038/tpj.2014.1. Epub 2014 Feb 11. Pharmacogenomics J. 2014. PMID: 24513691
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.
Volz NB, Stintzing S, Zhang W, Yang D, Ning Y, Wakatsuki T, El-Khoueiry RE, Li JE, Kardosh A, Loupakis F, Cremolini C, Falcone A, Scherer SJ, Lenz HJ. Volz NB, et al. Among authors: lenz hj. Pharmacogenomics J. 2015 Feb;15(1):69-76. doi: 10.1038/tpj.2014.40. Epub 2014 Jul 29. Pharmacogenomics J. 2015. PMID: 25069475 Clinical Trial.
CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy.
Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Ueno M, Mizunuma N, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Parekh A, Okazaki S, Berger MD, El-Khoueiry R, Mendez A, Ichikawa W, Loupakis F, Lenz HJ. Matsusaka S, et al. Among authors: lenz hj. Pharmacogenomics J. 2017 Dec;17(6):543-550. doi: 10.1038/tpj.2016.59. Epub 2016 Aug 9. Pharmacogenomics J. 2017. PMID: 27503580 Free PMC article.
Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.
Benhaim L, Gerger A, Bohanes P, Paez D, Wakatsuki T, Yang D, Labonte MJ, Ning Y, El-Khoueiry R, Loupakis F, Zhang W, Laurent-Puig P, Lenz HJ. Benhaim L, et al. Among authors: lenz hj. Pharmacogenomics J. 2014 Apr;14(2):135-41. doi: 10.1038/tpj.2013.21. Epub 2013 Jun 11. Pharmacogenomics J. 2014. PMID: 23752739
684 results